Research programme: inflammatory bowel disease therapeutics - Calypso Biotech

Drug Profile

Research programme: inflammatory bowel disease therapeutics - Calypso Biotech

Alternative Names: CALY-001; Gastrointestinal disorder antibody therapeutics - Calypso Biotech; Gastrointestinal immunological disease therapeutics - Calypso Biotech

Latest Information Update: 05 Apr 2017

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Calypso Biotech
  • Class Antibodies; Monoclonal antibodies
  • Mechanism of Action Matrix metalloproteinase 9 inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity Yes

Highest Development Phases

  • Research Crohn's disease
  • No development reported Inflammatory bowel diseases

Most Recent Events

  • 31 Mar 2017 CALY 001 licensed to EA Pharma worldwide
  • 16 Jul 2016 No recent reports of development identified for research development in Inflammatory-bowel-disease in Switzerland (Parenteral)
  • 01 Aug 2013 Early research in Crohn's disease in Switzerland (Parenteral)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top